[go: up one dir, main page]

ES2140336B1 - NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS. - Google Patents

NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Info

Publication number
ES2140336B1
ES2140336B1 ES9800043A ES9800043A ES2140336B1 ES 2140336 B1 ES2140336 B1 ES 2140336B1 ES 9800043 A ES9800043 A ES 9800043A ES 9800043 A ES9800043 A ES 9800043A ES 2140336 B1 ES2140336 B1 ES 2140336B1
Authority
ES
Spain
Prior art keywords
mutants
brucella abortus
brucella
strain
virulent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES9800043A
Other languages
Spanish (es)
Other versions
ES2140336A1 (en
Inventor
Goni Ignacio Lopez
Uria Ignacio Moriyon
Alberto Sola-Landa
Garcia Ramon Diaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES9800043A priority Critical patent/ES2140336B1/en
Publication of ES2140336A1 publication Critical patent/ES2140336A1/en
Application granted granted Critical
Publication of ES2140336B1 publication Critical patent/ES2140336B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Mutantes no virulentos de Brucella abortus. Se describen mutantes puntuales y estables obtenidos por inserción del transposón Tn5 en los genes de Brucella abortus bvrR y bvrS, un sistema de dos componentes regulador de la transducción. Los mutantes, son seleccionados por su sensibilidad a los péptidos canónicos bactericidas y agentes surfactantes. Dichos péptidos mantienen la característica lisa de su lipopolisacárido, pero son totalmente avirulentos en el modelo murino. Se obtienen cepas mutantes de Brucella abortus, en concreto la cepa 2.13 (NCTC 13091) con una inserción en el gen bvrS y la cepa 65.21 (NCTC 13092) con una inserción en el gen bvrR, ambos mutantes derivados de la cepa parental virulenta Brucella abortus 2308. El huésped natural de Brucella abortus es el ganado bovino, aunque también puede infectar a otros tipos de ganado e incluso al hombre. Estos mutantes pueden ser empleados por tanto, como vacunas contra la brucelosis, tanto en humanos como en animales. Además, por la capacidad adyuvante de Brucella pueden ser también empleados como vacunas recombinantes presentadoras de antígenos.Non-virulent mutants of Brucella abortus. Point and stable mutants obtained by insertion of the Tn5 transposon into the genes of Brucella abortus bvrR and bvrS, a two-component transduction regulatory system, are described. Mutants are selected for their sensitivity to bactericidal canonical peptides and surfactants. These peptides maintain the smooth characteristic of their lipopolysaccharide, but they are totally avirulent in the murine model. Mutant strains of Brucella abortus are obtained, specifically strain 2.13 (NCTC 13091) with an insertion in the bvrS gene and strain 65.21 (NCTC 13092) with an insertion in the bvrR gene, both mutants derived from the virulent parental strain Brucella abortus 2308. The natural host of Brucella abortus is cattle, although it can also infect other types of livestock and even man. These mutants can therefore be used as brucellosis vaccines, both in humans and animals. Furthermore, due to the adjuvant capacity of Brucella, they can also be used as recombinant antigen presenting vaccines.

ES9800043A 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS. Expired - Lifetime ES2140336B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9800043A ES2140336B1 (en) 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9800043A ES2140336B1 (en) 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Publications (2)

Publication Number Publication Date
ES2140336A1 ES2140336A1 (en) 2000-02-16
ES2140336B1 true ES2140336B1 (en) 2000-10-16

Family

ID=8302367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9800043A Expired - Lifetime ES2140336B1 (en) 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Country Status (1)

Country Link
ES (1) ES2140336B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9305970A (en) * 1992-02-25 1997-10-21 Texas A & M Univ Sys Enhanced vaccine against brucella abortus

Also Published As

Publication number Publication date
ES2140336A1 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
US11920139B2 (en) Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety
Perkins et al. Towards a Brucella vaccine for humans
Briones et al. Brucella abortus cyclic β-1, 2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells
Hong et al. Identification of genes required for chronic persistence of Brucella abortus in mice
Saxena et al. Pre-existing immunity against vaccine vectors–friend or foe?
Rajapakse et al. Immunization with the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model
Flashner et al. Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates
US7083794B2 (en) Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS positive phenotype
Vanloubbeeck et al. The immunology of Leishmania infection and the implications for vaccine development
US20080069843A1 (en) Salmonella vaccine
Temple et al. Bordetella avium virulence measured in vivo and in vitro
Baron et al. Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a
Rodríguez-Morales et al. Salmonella enterica serovar Typhimurium ompS1 and ompS2 mutants are attenuated for virulence in mice
Łaniewski et al. Evaluation of protective efficacy of live attenuated Salmonella enterica serovar Gallinarum vaccine strains against fowl typhoid in chickens
Moustafa et al. Recombinant Salmonella expressing Burkholderia mallei LPS O antigen provides protection in a murine model of melioidosis and glanders
Adler et al. Immunity and vaccine development in Pasteurella multocida infections
Cruz-Fisher et al. Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice
Bunch-Christensen et al. The virulence of some strains of BCG for golden hamsters
TR200002974T2 (en) Live vaccine against brucellosis
Campos et al. Brucella abortus INTA2, a novel strain 19 Δbp26:: luc Δbmp18 double mutant lacking drug resistance markers
Sanapala et al. Comparative evaluation of Salmonella Typhimurium vaccines derived from UK-1 and 14028S: Importance of inherent virulence
ES2140336B1 (en) NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.
Parida et al. Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model
Kohler et al. Oral immunization with recombinant Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutinin: effect of boosting on mucosal, systemic and immunoglobulin G subclass response
Saito et al. Complement-Mediated Killing ofPorphyromonas gingivalis381 by the Immunoglobulin G Induced by Recombinant 40-kDa Outer Membrane Protein

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000216

Kind code of ref document: A1

Effective date: 20000216

FA2A Application withdrawn

Effective date: 20031120